American People News

News that affects American households

Government

DEA places new narcolepsy drug Orzeyful in Schedule IV, saying its abuse potential resembles phentermine's

The interim rule took effect on November 12, putting Takeda's oveporexton in the same federal drug schedule as phentermine. Comments are due December 14.

By Government Desk · · 3 min read

What it means for you

  • An interim final rule effective November 12 places oveporexton, sold as Orzeyful, in Schedule IV of the Controlled Substances Act.
  • FDA approved Orzeyful on August 5, 2026, to treat narcolepsy type 1 in adults. DEA says no other drug that works the same way is listed under the law.
  • HHS and DEA concluded that its abuse potential is similar to that of phentermine, based on animal studies and a study in recreational drug users given doses above the prescribed range.
  • Patients who have a lawful prescription do not need to register with DEA, but prescriptions must follow the federal rules for controlled substances.
  • Comments and hearing requests are due by December 14, 2026. DEA must then issue a final rule.

The Drug Enforcement Administration has placed oveporexton, a new narcolepsy medicine sold under the brand name Orzeyful, in Schedule IV of the Controlled Substances Act. The interim final rule was published in the Federal Register on November 12 and took effect the same day, according to the government's printed copy. Schedule IV covers drugs that the law treats as having a low potential for abuse compared with Schedule III. DEA used phentermine, a Schedule IV stimulant, as its point of comparison.

The Food and Drug Administration approved Orzeyful on August 5, 2026, to treat narcolepsy type 1, according to the agency's list of novel drug approvals for the year. DEA's rule says the approval covers adults and that Takeda Pharmaceuticals U.S.A. submitted its application on December 10, 2025. The tablets come in 0.5, 1 and 2 milligram strengths, and the recommended dose is 1 or 2 milligrams taken after waking and again three to five hours later. The drug had recently been approved in China and Japan, DEA says.

Why the rule took effect at once

When a newly approved drug has a stimulant, depressant or hallucinogenic effect and the Department of Health and Human Services recommends controlling it, federal law requires DEA to issue an interim rule within 90 days, effective immediately. DEA says the purpose is to let such drugs be marketed without undue delay after approval. It received HHS's scientific evaluation and its recommendation for Schedule IV on July 31, 2026, and then completed its own review of the eight factors the law sets out.

What the agencies found

Oveporexton works by activating the brain's orexin type 2 receptors, and DEA says no other drug with that mechanism is listed under the law. In rats, it produced some stimulant-like behavior and weak reinforcing effects. In a study of recreational drug users with stimulant experience, doses of 18 and 30 milligrams, several times the recommended maximum of 4 milligrams a day, produced drug-liking scores that were not statistically different from those for a 75-milligram dose of phentermine. On that basis DEA concluded that oveporexton "has a potential for abuse similar to the schedule IV stimulant phentermine."

The rule also records what the agencies did not find. FDA and DEA say they know of no diversion or abuse of the drug, and DEA's national forensic laboratory database shows that law enforcement has not encountered it in the United States. Across six repeated-dose trials with 277 participants, HHS found no consistent sign of withdrawal, and DEA says the drug does not appear to produce substantial physical dependence.

DEA added a concern of its own. It cites a 2026 analysis in JAMA Neurology that found improved attention, memory and executive function after eight weeks in people with narcolepsy type 1, and says the potential for cognitive enhancement could make the drug more attractive for misuse, while noting that studies are needed to confirm whether the effects extend to people without the condition. Among patients taking recommended doses in Phase 3 trials, transient insomnia and more frequent urination occurred in a majority, according to DEA.

What changes for patients and pharmacies

Manufacturers, distributors, pharmacies and researchers that handle oveporexton must hold a DEA registration and follow Schedule IV rules on security, inventory, records and labeling. The rule says those requirements do not apply to patients who possess the drug under a lawful prescription. Prescriptions themselves must comply with the federal law on controlled-substance prescriptions and DEA's regulations in 21 CFR parts 1306 and 1311.

What comes next

Comments must be submitted electronically or postmarked by December 14, 2026, under docket DEA-1775 at regulations.gov, according to the rule, and requests for a hearing are due the same day. After those proceedings, the law requires DEA to issue a final rule. The Office of Management and Budget reviewed the rule as a significant regulatory action, though not an economically significant one. Our explainer on how a federal rule is made describes the comment process.

Sources

  1. Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV (interim final rule, 91 FR 72775) Drug Enforcement Administration, via the Federal Register (govinfo), November 12, 2026
  2. Novel Drug Approvals for 2026 U.S. Food and Drug Administration

Researched and drafted with AI assistance, then checked against the 2 sources above in a separate fact-check on November 15, 2026. Spotted an error? Tell us.